(PCR) PCC Rokita - Ratings and Ratios
Exchange: WAR • Country: Poland • Currency: PLN • Type: Common Stock • ISIN: PLPCCRK00076
PCR: Chemicals, Polyurethane, Chlorine, Alkali, Surfactants, Polyols
PCC Rokita SA is a Poland-based chemical manufacturer with a strong international presence. The company specializes in producing a wide array of chemical products, including chlorine and alkali, polyurethane insulation systems, and specialty surfactants. Its product portfolio caters to diverse industries such as agriculture, construction, electronics, and personal care, making it a key player in the commodity chemicals sector.
Founded in 1993, PCC Rokita has established itself as a reliable supplier to industries like adhesives, paints, and coatings. Its products are also used in fire prevention, water treatment, and even sports equipment. The company’s ability to serve multiple sectors reduces its reliance on any single market, which is a favorable trait for investors seeking stability.
From a financial perspective, PCC Rokita has a market capitalization of approximately 1.5 billion PLN, with a price-to-earnings ratio of 10.04. This indicates that the company is valued at a reasonable multiple relative to its earnings. Its price-to-book ratio of 1.21 suggests that investors are paying slightly more than book value for its assets, which could indicate confidence in its future prospects.
The company’s subsidiary relationship with PCC SE adds another layer of stability, as it benefits from the resources and expertise of its parent company. This structure can be appealing to fund managers looking for exposure to the chemical sector with a balance of growth and stability.
Additional Sources for PCR Stock
PCR Stock Overview
Market Cap in USD | 412m |
Sector | Basic Materials |
Industry | Chemicals |
GiC Sub-Industry | Commodity Chemicals |
IPO / Inception |
PCR Stock Ratings
Growth 5y | 52.1% |
Fundamental | 47.7% |
Dividend | 86.7% |
Rel. Strength Industry | -22.3 |
Analysts | - |
Fair Price Momentum | 88.53 PLN |
Fair Price DCF | 218.33 PLN |
PCR Dividends
Dividend Yield 12m | 8.35% |
Yield on Cost 5y | 37.58% |
Annual Growth 5y | 14.46% |
Payout Consistency | 87.6% |
PCR Growth Ratios
Growth Correlation 3m | 69.9% |
Growth Correlation 12m | -93.5% |
Growth Correlation 5y | 84.7% |
CAGR 5y | 33.48% |
CAGR/Max DD 5y | 0.80 |
Sharpe Ratio 12m | -0.20 |
Alpha | -26.12 |
Beta | 0.17 |
Volatility | 23.24% |
Current Volume | 1.3k |
Average Volume 20d | 1.6k |
As of March 15, 2025, the stock is trading at PLN 75.40 with a total of 1,284 shares traded.
Over the past week, the price has changed by -0.13%, over one month by -4.31%, over three months by +2.59% and over the past year by -25.09%.
Partly, yes. Based on ValueRay Fundamental Analyses, PCC Rokita (WAR:PCR) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 47.72 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PCR as of March 2025 is 88.53. This means that PCR is currently undervalued and has a potential upside of +17.41% (Margin of Safety).
PCC Rokita has no consensus analysts rating.
According to ValueRays Forecast Model, PCR PCC Rokita will be worth about 95.6 in March 2026. The stock is currently trading at 75.40. This means that the stock has a potential upside of +26.8%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 85 | 12.7% |
Analysts Target Price | - | - |
ValueRay Target Price | 95.6 | 26.8% |